250 related articles for article (PubMed ID: 21170361)
1. Identification of Y-box binding protein 1 as a core regulator of MEK/ERK pathway-dependent gene signatures in colorectal cancer cells.
Jürchott K; Kuban RJ; Krech T; Blüthgen N; Stein U; Walther W; Friese C; Kiełbasa SM; Ungethüm U; Lund P; Knösel T; Kemmner W; Morkel M; Fritzmann J; Schlag PM; Birchmeier W; Krueger T; Sperling S; Sers C; Royer HD; Herzel H; Schäfer R
PLoS Genet; 2010 Dec; 6(12):e1001231. PubMed ID: 21170361
[TBL] [Abstract][Full Text] [Related]
2. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
3. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
[TBL] [Abstract][Full Text] [Related]
4. RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function.
Schäfer R; Sers C
Adv Enzyme Regul; 2011; 51(1):126-36. PubMed ID: 21094659
[TBL] [Abstract][Full Text] [Related]
5. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
6. Interaction network analysis of YBX1 for identification of therapeutic targets in adenocarcinomas.
Murugesan SN; Yadav BS; Maurya PK; Chaudhary A; Singh S; Mani A
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180040
[TBL] [Abstract][Full Text] [Related]
7. YB-1, the E2F pathway, and regulation of tumor cell growth.
Lasham A; Samuel W; Cao H; Patel R; Mehta R; Stern JL; Reid G; Woolley AG; Miller LD; Black MA; Shelling AN; Print CG; Braithwaite AW
J Natl Cancer Inst; 2012 Jan; 104(2):133-46. PubMed ID: 22205655
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
Lai YW; Hsu WJ; Lee WY; Chen CH; Tsai YH; Dai JZ; Yang CC; Lin CW
Cells; 2021 Jul; 10(8):. PubMed ID: 34440660
[TBL] [Abstract][Full Text] [Related]
9. RP11-296E3.2 acts as an important molecular chaperone for YBX1 and promotes colorectal cancer proliferation and metastasis by activating STAT3.
Shi Q; He Y; He S; Li J; Xia J; Chen T; Huo L; Ling Y; Liu Q; Zang W; Wang Q; Tang C; Wang X
J Transl Med; 2023 Jun; 21(1):418. PubMed ID: 37370092
[TBL] [Abstract][Full Text] [Related]
10. PRMT5-mediated methylation of YBX1 regulates NF-κB activity in colorectal cancer.
Hartley AV; Wang B; Mundade R; Jiang G; Sun M; Wei H; Sun S; Liu Y; Lu T
Sci Rep; 2020 Sep; 10(1):15934. PubMed ID: 32985589
[TBL] [Abstract][Full Text] [Related]
11. Serine-threonine Kinase Receptor-Associated Protein is a Critical Mediator of APC Mutation-Induced Intestinal Tumorigenesis Through a Feed-Forward Mechanism.
Vu T; Datta A; Banister C; Jin L; Yuan G; Samuel T; Bae S; Eltoum IE; Manne U; Zhang B; Welner RS; Mitra K; Buckhaults P; Datta PK
Gastroenterology; 2022 Jan; 162(1):193-208. PubMed ID: 34520730
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.
Kuwano M; Shibata T; Watari K; Ono M
Cancer Sci; 2019 May; 110(5):1536-1543. PubMed ID: 30903644
[TBL] [Abstract][Full Text] [Related]
13. Mutual regulation between Raf/MEK/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression.
Imada K; Shiota M; Kohashi K; Kuroiwa K; Song Y; Sugimoto M; Naito S; Oda Y
Clin Cancer Res; 2013 Sep; 19(17):4638-50. PubMed ID: 23838318
[TBL] [Abstract][Full Text] [Related]
14. Delineation of gastric tumors with activated ERK/MAPK signaling cascades for the development of targeted therapeutics.
Pandian J; Ganesan K
Exp Cell Res; 2022 Jan; 410(1):112956. PubMed ID: 34864005
[TBL] [Abstract][Full Text] [Related]
15. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
16. YBX1, Targeted By Microrna-382-5p, Promotes Laryngeal Squamous Cell Carcinoma Progression
Zeng W; Pan Y; Chen H; Lei X; Zhang X
Recent Pat Anticancer Drug Discov; 2024; 19(2):176-187. PubMed ID: 38214357
[TBL] [Abstract][Full Text] [Related]
17. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
[No Abstract] [Full Text] [Related]
18. Identification of transcription factor binding sites upstream of human genes regulated by the phosphatidylinositol 3-kinase and MEK/ERK signaling pathways.
Tullai JW; Schaffer ME; Mullenbrock S; Kasif S; Cooper GM
J Biol Chem; 2004 May; 279(19):20167-77. PubMed ID: 14769801
[TBL] [Abstract][Full Text] [Related]
19. Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway.
Chu PC; Lin PC; Wu HY; Lin KT; Wu C; Bekaii-Saab T; Lin YJ; Lee CT; Lee JC; Chen CS
Oncogene; 2018 Jun; 37(25):3440-3455. PubMed ID: 29559746
[TBL] [Abstract][Full Text] [Related]
20. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
